ALZHEON, INC. filed a Form D with the Securities and Exchange Commission on 2026-09-10.
ALZHEON, INC. filed a Form D notice of an exempt securities offering with the SEC on September 10, 2026. The filing reports $78.80M sold. Its industry group is Biotechnology. It names Martin Tolar, M.D., Ph.D. (President and Chief Executive Officer), Christopher Dunn (Director), Neil Flanzraich (Director) (SEC Form D, September 10, 2026).
Sell to companies like ALZHEON, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ALZHEON, INC.
Free to see. No signup.
More on the people and the money behind ALZHEON, INC., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in September 2026, largest first.
Get an email when ALZHEON, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ALZHEON, INC. raises, hires or launches. No email unless you switch it on.
Watch ALZHEON, INC. →Get the full cited report on ALZHEON, INC.
What the filing shows about ALZHEON, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ALZHEON, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for ALZHEON, INC. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week. The dot is this raise, $78.80M, on the same scale — one filing against the whole group's total, so it sits low by construction.
By form type: D ×10 · D/A ×5 · S-1/A ×4 · RW ×2 · FWP ×2 · S-1 ×2 · DRS/A ×2 · 8-A12B ×2, and others.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-10 | open |
| D/A | 2025-02-10 | open |
| D/A | 2025-01-02 | open |
| D | 2024-03-12 | open |
| D | 2023-01-11 | open |
| D | 2020-09-30 | open |
| D | 2020-01-15 | open |
| RW | 2019-01-16 | open |
| FWP | 2018-11-02 | open |
| S-1/A | 2018-11-02 | open |
What the filing shows about ALZHEON, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ALZHEON, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ALZHEON, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 10 most recent of 31 filings on CIK 0001582636, filed as ALZHEON, INC.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Checked away from the filing. What is below does not come from the record on sec.gov.
Alzheon is committed to developing breakthrough medicines for patients suffering from Alzheimer's disease and other neurological disorders.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Martin Tolar, M.D., Ph.D. is named as President and Chief Executive Officer on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
Christopher Dunn is named as Director on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
Neil Flanzraich is named as Director on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
Jordan Heller is named as Director on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
Diane Jorkasky, M.D. is named as Director on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
Gino Santini is named as Director on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
Muneer Satter is named as Director on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Kenneth Mace is named as Treasurer and Chief Financial Officer on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Susan Abushakra, M.D. is named as Chief Medical Officer on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
John Hey, Ph.D. is named as Chief Scientific Officer on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Aidan Power, MRCPsych is named as Chief Development Officer on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Adem Albayrak is named as Chief Data Officer on the Form D that ALZHEON, INC. filed with the SEC on 10 September 2026, one of 12 people that filing names.
12 people named on the filing — 6 holding an executive role and 6 as directors only.
Named as of the 2026-09-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ALZHEON, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind ALZHEON, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (alzheon.com).
Each opens in a new tab, filled in for ALZHEON, INC.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-09-07 · Biotech raises in Boston
https://mentionfox.com/funding/alzheon-inc-form-d-000002